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THERAPEUTIC APPROACH IN ACUTE CORONARY
SYNDROME FOCUSING ON ORAL THERAPY*
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Department of Cardiology, University Department of Medicine, Sestre milosrdnice University Hospital,
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SUMMARY – In the light of some new information based on clinical evidence, current the-
rapeutic approach to patients with acute coronary syndrome especially focusing on oral therapy is 
being considered. Th e initial stage of treatment does not diff er greatly among patients with unstable 
angina pectoris (UA), non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myo-
cardial infarction (STEMI). It is necessary to simultaneously resolve a series of problems within 
the fi rst twenty minutes upon admission, i.e. risk assessment, selection of treatment strategy (con-
servative, invasive), relief of ischemic pain, determination of hemodynamic status and eliminati-
on of any undesired complications (hypertension, tachycardia, heart failure), and administration 
of antithrombotic therapy. Patients suff ering from STEMI require reperfusion treatment, and the 
method of choice is primary percutaneous coronary intervention (PCI) where available. Fibrinolytic 
reperfusion therapy is limited exclusively to STEMI within the fi rst three hours from the onset of 
pain. Unlike this, in patients suff ering from UA/NSTEMI it is necessary to make risk assessment 
in the early stage of disease, and thus select the patients that will certainly benefi t from invasive tre-
atment through PCI. For pain relief, the patient should be immediately administered nitroglycerin 
along with oxygen. Beta-blockers that are reasonably used in the initial stage of treatment during 
the fi rst 24 hours, if not contraindicated, are still underused. Clopidogrel becomes an obligatory 
drug not only in patients having undergone PCI, but also in those treated conservatively following 
fi brinolysis. 
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Introduction 
Th e initial therapeutic approach to a patient suf-
fering from acute coronary syndrome (ACS) does not 
greatly diff er, i.e. it is principally identical, regardless 
of whether unstable angina pectoris (UA), non-ST-el-
evation myocardial infarction (NSTEMI), or ST-ele-
vation myocardial infarction (STEMI) is concerned. 
However, it is worth mentioning that fi brinolytic rep-
erfusion therapy is limited only to STEMI within the 
fi rst three hours from the onset of pain, whereas in 
patients with NSTEMI it is ineffi  cient and may even 
be harmful. On drug dosing, attention should be paid 
to patient age, especially due to the fact that drugs are 
excreted through kidneys, however, adaptation is not 
necessary when applying dual antiaggregation therapy 
with aspirin and clopidogrel.
* Th e lecture was presented at the Emergencies in Cardiovascular 
Medicine Symposium, held on September 29, 2008 in Zagreb 
under the auspices of the Working Group for Acute Coronary 
Syndrome of the Croatian Cardiac Society.
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When the diagnosis of ACS has been made, an op-
timal initial approach within the fi rst twenty minutes 
should include urgent and simultaneous resolution of 
a number of problems1,2, i.e. risk assessment, selection 
of treatment strategy (conservative, invasive), pain re-
lief, determination of patient hemodynamic status and 
elimination of any undesired complication (hyperten-
sion, tachycardia, heart failure, hypotension, cardio-
genic shock), and starting antithrombotic therapy. 
Initial Assessment
In patients suff ering from UA/NSTEMI, it is nec-
essary to make a disease risk assessment in the early 
stage of the disease, or rather, select the patients that 
will undoubtedly have a better prognosis with invasive 
treatment by applying percutaneous coronary inter-
vention (PCI). In high risk patients, the intervention 
is to be done within 48 hours and in the others this 
procedure may be delayed until another hospitaliza-
tion. Since recently, patients with UA/NSTEMI are 
urgently managed during the fi rst 48 hours of hospital 
treatment at PCI centers. Clinical testing has identi-
fi ed a number of factors that help us select such pa-
tients: ECG changes as depression and extension of 
changes to ST segment, an increased value of myocar-
dial necrosis markers, hemodynamic instability, and 
persistent chest pain resistant to therapy. Th e use of 
such factors has led to the development of risk score 
tables such as TIMI, GRACE and PURSUIT, of 
which we consider TIMI risk score as being especially 
worth quoting (Table 1)1,3-8. Each variable is scored 
with one point. Low risk is scored 0-2, medium risk 
3-4, and high risk 5-7 points. Irrespective of this, 
two variables indicate urgent PCI although their sum 
is only two points; these two variables are dynamic 
changes to ST segment on ECG and increased tro-
ponin values.
Elimination of Ischemic Pain
Upon making the diagnosis and ACS risk assess-
ment, ischemic pain relief or elimination should be 
simultaneously initiated. Besides oxygen, the patient 
should be immediately administered sublingual nitro-
glycerine as necessary, even three times consecutively 
at 5-minute intervals; if the pain is not eased or in the 
event of hypertensive blood pressure values or heart 
failure, intravenous (i.v.) administration that may con-
tinue for the next 24-48 hours should be undertaken9-
11. Nitrates may be dangerous if used in patients with 
right ventricular infarction12, or in patients with aortic 
stenosis, and they must be withheld when the systolic 
pressure values are 100 mm Hg or lower, and in the 
event of a rise in cardiac frequency exceeding 100/
min13. Th e nitrate side eff ects are headache, orthostatic 
hypotension (following the second dose, the patient is 
advised to sit or lie down), and paradoxical bradycardia 
with hypotension, which are very successfully elimi-
nated by reducing the dose and giving an analgesic if 
anginal pain recurs, and in the event of bradycardia 
i.v. atropine as necessary. Nitrate therapy administered 
over a longer period of time to up to several weeks 
with no therapeutic benefi t (especially in terms of pain 
elimination) proved to be purposeless and did not re-
duce mortality as compared with placebo11.
In the initial stage of disease when applying fur-
ther therapeutic algorithm, i.v. morphine is the drug 
of choice, complying with the rule that the systolic 
pressure values need to exceed 100 mm Hg. One 
ampule of 1 mL/10 mg diluted in 9 mL 0.9% NaCl 
should be administered i.v. and repeatedly adminis-
Table 1. Risk score in UA/NSTEMI-TIMI risk score (according to Antman et al.8)
Variable Number of points
Age ≥65 years 1
Presence of minimum three cardiovascular risk factors (hypertension, diabetes, smoking and 
family history of coronary artery disease)
1
Coronary artery stenosis >50% proven on coronary angiogram 1
ST-segment deviation on ECG 1
At least two anginal events in the last 24 hours 1
Elevated cardio-selective markers 1
Administration of aspirin for the last seven days 1
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tered fractionally with 2 mL/2 mg at 5-minute inter-
vals until the pain is eased. Th e eff ect occurs after 20 
minutes. Morphine is contraindicated in cardiogenic 
shock. All such therapeutic actions require patient 
bed rest and observation, when possible, followed by 
continuous monitoring of ECG rhythm to follow up 
arrhythmias and dynamic ECG changes1.
Beta Blocking Agents
Agents that are insuffi  ciently used are beta-adren-
ergic blocking agents (beta-blockers) which, accord-
ing to some recent guidelines of the European and 
American Cardiac Societies, are reasonably used in 
the initial stage of treatment, during the fi rst 24 hours 
if not contraindicated (Fig. 1). Patients should be he-
modynamically stable. Beta-blockers i.v. are recom-
mended for the fi rst 24 hours, especially in patients 
with persisting anginal pain, hypertension or tachy-
cardia and no signs of cardiac insuffi  ciency. Cardi-
oselective beta-blockers are mostly concerned (meto-
prolol, atenolol and bisoprolol). In further treatment 
of stable patients, these agents are administered per 
os, with careful dosing (for example, the initial dose 
of atenolol is 12.5 mg and of bisoprolol 1.25 mg)1,14. 
Beta-blockers should be administered to all patients 
with reduced ejection fraction15. In such cases, carve-
dilol proved to be benefi cial.
Oral Antithrombotic Th erapy
In the initial stage of acute coronary syndrome, 
therapy of choice is dual antiaggregation medication 
to prevent progression of thrombosis or embolization 
with ulcerated plaque. All patients receive aspirin, 
usually in a dose of 100 mg on a daily basis. Th e fi rst 
dosage of 300 mg needs to be chewed, even in pa-
tients with gastrointestinal problems. Aspirin is well 
and quickly absorbed from the stomach and small in-
testine. Today, agents with lesser eff ects on mucous 
membrane are available, therefore rarely showing 
gastrointestinal side eff ects. Th is mode of treatment 
is combined with clopidogrel administered with ei-
ther low molecular weight heparin or selective factor 
X blocker, fondaparinux, or glycoprotein IIb/IIIa in-
hibitor, all of which increase the tendency to hemor-
rhagic complications. Of course, patients with STE-
MI treated with fi brinolytic therapy should not be left 
unobserved. Gastrointestinal bleeding and very rarely 
other sites of bleeding (intracranial hemorrhage, ret-
Fig. 1. Eff ect of beta-adrenergic blockers on heart rate and arrhythmia (left: prior to beta-blocker therapy, 110 beats/min; 
right: after beta-blocker therapy, 67 beats/min).
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roperitoneal hematoma) severely aff ect ACS patients 
treated with PCI during which one or more stents have 
been implanted, since antithrombotic therapy should 
be discontinued in the event of serious bleeding. In the 
event of therapy interruption, these patients show an 
increased tendency of procoagulation eff ect, i.e. a re-
bound phenomenon with consequential stent throm-
bosis16. Although it has not yet been systematically 
investigated whether prophylaxis with proton pump 
inhibitors (PPI) may reduce the risk of bleeding from 
digestive tract, in the last few years PPI have been in-
creasingly administered to patients with an increased 
risk of bleeding17. Th e guidelines issued in 2007 by 
the American Cardiac Society (ACC/AHA) for un-
stable angina and NSTEMI expressly recommend 
prophylactic administration of PPI, however, with-
out specifying the length of treatment. Th e conclu-
sion is: PPI needs to be prophylactically administered 
in patients with an increased risk of gastrointestinal 
bleeding, including the elderly with a history of ulcer 
disease, previous use of nonsteroidal antirheumatics, 
liver disease, and thrombocytopenia1. Th e interaction 
between clopidogrel and PPI is clinically relevant and 
therefore PPI should only be administered in patients 
at a high risk of gastrointestinal bleedingl8.
If the patient does not tolerate aspirin, clopidogrel 
is used as monotherapy. In daily practice, based on 
a number of positive clinical evidence, clopidogrel is 
administered immediately following aspirin. It is an 
agent that is included in the group of thienopyridine 
derivatives; it blocks adenosine-diphosphate recep-
tors on platelet surface and acts synergistically with 
aspirin. Such dual antithrombotic therapy prevents 
platelet adhesion and aggregation. In patients that are 
not scheduled for early coronarography, clopidogrel is 
administered in a loading dose of 300 mg orally, fol-
lowed by the maintenance dose of 75 mg per day. If an 
emergency cardiac procedure is needed, the loading 
dose of clopidogrel is 600 mg. Such a manner of tak-
ing clopidogrel at once contributes to achieving maxi-
mum eff ect as early as within 2-3 hours, unlike 300 
mg that starts to take eff ect only after 12 hours19,20. 
Th e phenomenon of resistance to clopidogrel has been 
mentioned recently, however, the increase in the com-
mon maintenance dose from 75 to 150 mg (2 tablets) 
reduces resistance from approximately 30% to only 
12% of patients. An urgent, primary PCI in patients 
with NSTEMI, especially those with a lower or in-
termediary risk score, as mentioned above, may be de-
layed. Th is delay is based on the fact that some patency 
of the aff ected coronary artery is maintained in 60%-
85% of NSTEMI patients. Regardless of the possi-
bility to perform an immediate or delayed interven-
tion, or only conservative treatment in patients with 
NSTEMI, in compliance with the 2007 Guidelines 
of the European Cardiac Society, clopidogrel should 
be prescribed throughout the next 12 months, unless 
there is a high risk of bleeding. Such recommenda-
tions are based on the fi ndings of the CURE study, 
which monitored 12,565 patients with NSTEMI in-
farction for a period of 12 months. Th e relative risk 
of mortality with the administration of conservative 
therapy alone including clopidogrel in comparison 
with placebo was reduced by 17% at 12 months, and 
following PCI with clopidogrel in comparison with 
the group treated only conservatively with placebo by 
29%21. It is worth mentioning that in patients treated 
with clopidogrel and scheduled for bypass surgery, 
clopidogrel should be interrupted and surgery delayed 
by 5 days, if clinically acceptable.
During the last few years, especially after 2005 
when the COMMIT study fi ndings were published, 
the attitude towards therapy with clopidogrel in 
STEMI infarction has changed. Since then, in clini-
cal practice clopidogrel has unfortunately still been 
limited to patients undergoing PCI with stent im-
plantation. Th e study included 46,000 patients with 
acute myocardial infarction treated with noninvasive 
approach, with fi brinolysis performed in some 50% of 
cases. Study results showed a combination of 75 mg of 
clopidogrel with aspirin for a period of 28 days (with-
out prior loading dose of clopidogrel) to have reduced 
mortality at 4 weeks as compared with in the group of 
patients without clopidogrel by 7% and probability of 
reinfarction by 9%, while the incidence of cerebral or 
other fatal bleeding did not increase, i.e. there was no 
need of blood transfusion even in patients aged over 
75 that had been treated with fi brinolytic therapy. Th e 
second extension of this study, CLARITY TIMI 28, 
with invasive monitoring of 3491 patients treated with 
fi brinolytic therapy followed by clopidogrel therapy 
showed some interesting fi ndings after 28 days. Cor-
onarography performed 2 to 8 days after the infarc-
tion showed the rate of occlusion of target coronary 
artery, i.e. the artery responsible for infarction, to be 
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lower by 36% in patients that had been treated with 
clopidogrel as compared with those not treated with 
clopidogrel following fi brinolysis22.
Based on these and some other data, therapeutic 
administration of clopidogrel has greatly increased 
and is not limited to patients having undergone PCI 
with stent implantation anymore.
Other Oral Th erapies of Acute Coronary Syndrome
Besides statins, which will be discussed elsewhere, 
angiotensin-converting enzyme inhibitors (ACE in-
hibitors) or, in case of patient intolerance (usually due 
to cough) angiotensin-II receptor blockers (ARB) are 
drugs that should not be forgotten23,24. Th e favorable 
eff ect of ACE inhibitors and ARB in patients with 
acute myocardial infarction is primarily attributed 
to their role in slowing down, or rather stopping the 
post-infarction myocardial remodeling, especially in 
patients with anterior wall infarction or reduced left 
ventricular ejection fraction (LVEF) <40% and heart 
failure. Among numerous studies of the effi  cacy of 
ACE inhibitors in acute STEMI, note should be made 
of three trials performed with the widely available 
agents lisinopril11, ramipril25 and trandolapril26. Early 
administration of ACE inhibitors is recommended, 
not necessarily within the fi rst 24 hours, in order to 
avoid follow up hypotension. When reasonably used, 
these agents are well tolerated and lead to great re-
duction in mortality within 4-6 weeks of myocardial 
infarction. Th e dose should be gradually increased, 
depending on pressure values and kidney function 
tests. ACE inhibitors are used in unstable angina and 
NSTEMI patients with diabetes, heart failure, LVEF 
<40% and hypertension.
Th e use of verapamil, a calcium channel blocker, 
is limited to patients in the early stage of disease with 
atrial fi brillation and high ventricular rate and without 
signs of heart failure, if beta-blockers are contraindi-
cated. Amlodipine with no negative inotropic eff ects 
may be used in ACS if hypertension is not properly 
controlled by beta-blockers and ACE inhibitor27.
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Sažetak
TERAPIJSKI PRISTUP KOD AKUTNOG KORONARNOG SINDROMA USREDOTOČEN
NA ORALNU TERAPIJU
V. Nikolić Heitzler i M. Pavlov
U svjetlu nekih novih podataka zasnovanih na kliničkim dokazima razmatra se terapijski pristup bolesnicima s akut-
nim koronarnim sindromom koji se osobito oslanja na oralnu terapiju. U početnoj fazi liječenja nema većih razlika u 
pristupu bolesnicima s nestabilnom pektoralnom anginom, infarktom miokarda bez povišenja ST segmenta (NSTEMI) 
ili infarktom miokarda s povišenjem ST segmenta (STEMI). Istodobno treba razriješiti niz problema unutar prvih dva-
desetak minuta od prijma bolesnika: procjenu rizika, odabir strategije liječenja (konzervativno, invazivno), ublažavanje 
ishemijske boli, određivanje hemodinamskog statusa i uklanjanje neželjenih komplikacija (hipertenzija, tahikardija, srčano 
zatajenje), te davanje antitrombotske terapije. Bolesnici koji imaju STEMI zahtijevaju liječenje reperfuzijom, a metoda 
izbora je primarna perkutana koronarna intervencija (PCI) tamo gdje je dostupna. Fibrinolitička reperfuzijska terapija je 
ograničena isključivo na STEMI unutar prva tri sata od nastupa boli. Za razliku od toga, kod bolesnika s nestabilnom 
pektoralnom anginom/NSTEMI treba procijeniti rizik u ranom stadiju bolesti te tako odabrati one bolesnike kod kojih će 
invazivno liječenje pomoću PCI zasigurno biti korisno. Uz kisik bolesniku treba smjesta dati nitroglicerin radi ublažavanja 
boli. Primjena beta blokatora je razumna u početnoj fazi liječenja tijekom prva 24 sata, ako nisu kontraindicirani, no oni 
se još uvijek nedostatno primjenjuju. Klopidogrel postaje obvezatan lijek ne samo u bolesnika podvrgnutih PCI, nego isto 
tako u bolesnika koji se liječe konzervativno nakon fi brinolize.
Ključne riječi: Akutni koronarni sindrom – terapija lijekovima; Način davanja – peroralno; Akutni koronarni sindrom – kom-
plikacije; Koronarna bolest – terapija lijekovima
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